BCM
ORIC icon

Bridgeway Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Bridgeway Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,500
Closed -$207K – 1357
2023
Q4 		$207K Sell
22,500
-26,200
-54% -$189K ﹤0.01% 1130
2023
Q3 		$295K Sell
48,700
-56,500
-54% -$463K 0.01% 1014
2023
Q2 		$816K Hold
105,200
– – 0.02% 778
2023
Q1 		$600K Hold
105,200
– – 0.02% 845
2022
Q4 		$620K Buy
105,200
+40,500
+63% +$137K 0.02% 846
2022
Q3 		$207K Buy
+64,700
New +$259K 0.01% 1138

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridgeway Capital Management's ORIC Position: Q1 2024 in Review

Bridgeway Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q1 2024, closing a stake of 22,500 shares — an estimated $207K sold.

Bridgeway Capital Management first reported a position in ORIC in Q3 2022 and held it in 6 quarters. The position peaked at $816K in Q2 2023. 112 funds tracked by Wall St. Rank hold ORIC as of Q1 2024.

  • Bridgeway Capital Management reported no remaining Oric Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 22,500 Oric Pharmaceuticals shares in Q1 2024, an estimated $207K.
  • Bridgeway Capital Management first reported a position in Oric Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Bridgeway Capital Management's Oric Pharmaceuticals position peaked at $816K in Q2 2023.
  • 112 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2024.

Based on Bridgeway Capital Management's 13F filing for Q1 2024, filed 15 May 2024.